Influence of Carnicor, Venofer, and Sevelamer on the levels of genotoxic damage in end-stage renal disease patients

Susana Pastor, Elisabeth Coll, Lara Rodríguez-Ribera, Elitsa Stoyanova, Zuray F. Corredor, Ricard Marcos

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


© 2018 Wiley Periodicals, Inc. End-stage renal disease (ESRD) patients present high levels of phosphorus and calcium products in serum, which contribute to the development of vascular calcification and cardiovascular disease, and to low iron stores and carnitine deficiency. For these reasons, ESRD patients are generally supplemented with different medicines. Some of the most common treatments include the use of Carnicor, Venofer, and Sevelamer drugs. Carnicor is used as a source of L-carnitine, acting as antioxidant and neuroprotector. Venofer is used to reduce the deficit of iron. Sevelamer is used to treat hyperphosphatemia. To determine the potential harmful genotoxic effects of these drugs, a group of 214 patients included in a hemodialysis program with different intakes of Carnicor, Venofer, and Sevelamer were evaluated. The levels of basal and oxidative DNA damage, as well as chromosomal damage, were measured in all individuals using the comet and the micronucleus assays, respectively. Our results indicate that Carnicor administration was associated with low but significant increases in the frequency of basal DNA damage and micronuclei. Environ. Mol. Mutagen. 59:302–311, 2018. © 2018 Wiley Periodicals, Inc.
Original languageEnglish
Pages (from-to)302-311
JournalEnvironmental and Molecular Mutagenesis
Issue number4
Publication statusPublished - 1 May 2018


  • Carnicor
  • ESRD patients
  • Sevelamer
  • Venofer
  • comet assay
  • micronucleus assay


Dive into the research topics of 'Influence of Carnicor, Venofer, and Sevelamer on the levels of genotoxic damage in end-stage renal disease patients'. Together they form a unique fingerprint.

Cite this